News Update: MSD confirms $10bn takeover deal for Verona Pharma MSD has agreed a $10bn takeover offer for respiratory drug specialist Verona Pharma and its fast-growing COPD therapy Ohtuvayre.
News GSK claims first approval for Nucala in COPD GSK gets FDA approval for Nucala in COPD, setting up a marketing tussle with Sanofi/Regeneron's Dupixent.
News Stopwatch starts on reviews of GSK's long-acting asthma drug Regulators have started reviews of GSK's depemokimab, aiming to become the first drug for asthma that can be dosed twice a year.
News Verona says COPD drug is off to a flying start Verona Pharma's plans to transform COPD treatment with recently approved Ohtuvayre look like they are on course, given early sales figures.
Digital Digital biomarkers: Redefining respiratory care Respiratory diseases, common examples of which include asthma and chronic obstructive pulmonary disease (COPD), affect one in five people in the UK.1 The economic burden of these
News Study finds AZ's benralizumab a 'game-changer' in asthma Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if it was used to treat acute asthma attacks
News UK project addresses capacity issue in CGT manufacturing A UK consortium has been set up to tackle a major issue in the development of cell and gene therapies (CGT) – a lack of manufacturing capacity.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
